title: Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation.
abstract: BACKGROUND
  KCNJ11 mutations are a common cause of diabetes diagnosed in the first 6 months of life, and approximately 25% of patients have neurological features. Sulphonylureas have been shown to improve glycaemic control and also motor function, but the impact on cognitive function has not been extensively addressed previously.
  
  
  METHODS
  The patient had a low birth weight and was found to have diabetes at the age of 2 days. The patient was treated with insulin from diagnosis. The child also had marked developmental delay so that his average functional age was 2.5 years when he was 12 years old. A V59M mutation in KCNJ11 was found on sequencing, resulting in a diagnosis of intermediate developmental delay, epilepsy, neonatal diabetes (DEND) syndrome. Identification of a Kir6.2 mutation allowed insulin injections to be replaced by glibenclamide tablets.
  
  
  RESULTS
  This resulted not only in improved glycaemic control (HbA(1c) fell from 8.1 to 6.5%), but also an impressive improvement in many aspects of cognitive function, with the functional age increasing to 4 years within 6 months of treatment change.
  
  
  CONCLUSIONS
  This is the first clear report of cognitive function improving in a patient with the neurological features associated with a K(ATP) channel mutation following transfer to sulphonylureas. The finding of cognitive improvement suggests that glibenclamide is likely to be acting directly on the brain and not just on nerve and muscle, improving muscle strength.
authors.affiliation: Institute of Biomedical and Clinical Sciences, Peninsula Medical School, Exeter, UK. annabelleslingerland@hetnet.nl
authors.forename: A S
authors.initials: AS
authors.lastname: Slingerland
authors.forename: W
authors.initials: W
authors.lastname: Hurkx
authors.forename: K
authors.initials: K
authors.lastname: Noordam
authors.forename: S E
authors.initials: SE
authors.lastname: Flanagan
authors.forename: J W
authors.initials: JW
authors.lastname: Jukema
authors.forename: L C
authors.initials: LC
authors.lastname: Meiners
authors.forename: G J
authors.initials: GJ
authors.lastname: Bruining
authors.forename: A T
authors.initials: AT
authors.lastname: Hattersley
authors.forename: M
authors.initials: M
authors.lastname: Hadders-Algra
mesh_terms: D001921:Brain / Q000187:drug effects; D003071:Cognition / Q000187:drug effects*; D002658:Developmental Disabilities / Q000188:drug therapy / Q000235:genetics*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000235:genetics* / Q000523:psychology; D020022:Genetic Predisposition to Disease; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D009154:Mutation / Q000235:genetics*; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D000099161:Kcnj11 Channel
chemical_list: D024661:Potassium Channels, Inwardly Rectifying; D013453:Sulfonylurea Compounds; D000099161:Kcnj11 Channel